Tools


Sitemap

Sitemap

Webinar: Role of TSI Testing in Graves’ Disease Diagnosis

Healthcare News | 2013-04-29

image

Graves’ disease is an autoimmune disorder that leads to overactivity of the thyroid gland. It is the most common cause of hyperthyroidism. Graves’ disease is 5-10 times more prevalent in women than men, and affects 2-5% of all women. Left untreated, Graves’ disease can lead to miscarriage, birth defects, thyroid eye disease, and can be life-threatening. Proper diagnosis is crucial to ensure the appropriate treatment is administered as soon as possible.

The thyroid stimulating immunoglobulin (TSI) is an autoantibody that causes Graves’ hyperthyroidism. The TSI assay has been proven to have high specificity and sensitivity, aiding in the differential diagnosis of Graves’ disease.This webinar will focus on Graves’ disease diagnosis and monitoring, and will provide detailed information on the TSI assay, including relevant case studies.

Speaker:   Manjula Gupta, PhD

Professor of Pathology and Medicine, CCI College of Medicine

Medical Director, Endo/Immunology Labs Clinical Pathology, Cleveland Clinic

Date:   Wednesday, May 22, 2013

Time:   2:00 p.m. EDT (U.S.) / 8:00 p.m. CEST (Europe)

Register here

This webinar will be available for replay starting the day after the event. All who register for the event can access the webinar replay at any time.

Webinar learning objectives:

- Provide an overview of thyroid autoimmunity with focus on Graves’ disease

- Summarize current assay techniques for measuring TRabs (TBII and TSI)

- Describe the differences in the utilization of the TBII and TSI assays

- Discuss the benefit of incorporating the TSI test in the differential diagnosis of Graves’ disease.

Contact Center

International (English): +49 69 797 6602
You can call us Monday through Friday
8 am to 5 pm CET

There is a charge of $10.00 plus local tax for each half or full hour of CE credit. Purchase of CE credit is optional. Non-accredited participation in Siemens educational offerings and programs remains complimentary.

Did this information help you?
Thank you for your response
We detected numbers and/or an '@' symbol in your comment. Are you trying to enter a phone number or email address so that we may contact you, please contact us via our email form instead.

Note: to get a direct personal response, please contact us via our email form.

Thank you